Cancer Conversations™: Experts Discuss and Debate Optimal Treatment of Relapsed/Refractory Multiple Myeloma

Download All
Engage with an on-demand recording of a live Webinar on R/R MM featuring a faculty moderator interviewing 2 expert faculty about key areas of consensus and controversy. Download the slides, read a related expert commentary, and listen to a podcast from the Webinar.
Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD
Saad Z. Usmani, MD, MBA, FACP

On-Demand Webcast

Watch this on-demand webcast from a live webinar where experts discussed and debated the latest data for the management of patients with relapsed or refractory myeloma.

Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: March 31, 2021 Expired: March 30, 2022

Downloadable Slidesets

Download these slides from a live Webinar for up-to-date data on the optimal treatment options for patients with relapsed or refractory myeloma, including treatment algorithms and data on emerging therapies.

Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP
Released: March 15, 2021

Gain key clinical insights fast, with this short slideset from CCO summarizing current and emerging treatment options for patients with relapsed or refractory myeloma.

Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP
Released: March 17, 2021

ClinicalThought

With rapid advances and new drug approvals, it is increasingly challenging to select treatment for advanced myeloma. Read our conversation on current best practices.

Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP
Released: March 29, 2021
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
Bristol-Myers Squibb
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Oncopeptides

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue